Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|April 8, 2018
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 DeficiencyCheng-Yu Tsai, Si Sun, Hongying Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cellsRoohangiz Safaei, Kuniyuki Katano, Barrett J Larson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2023
Exploiting the Receptor-Binding Domains of R-Spondin 1 to Target Leucine-Rich Repeat-Containin G-Coupled Protein Receptor 5-Expressing Stem Cells in Ovarian CancerClara Wong, Maria Carmen Mulero, Erika I Barth, et al.
Cancer Chemotherapy and Pharmacology|February 20, 2007
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patientsMario Campone, Jeany M Rademaker-Lakhai, Jaafar Bennouna, et al.
NPJ Systems Biology and Applications|June 17, 2022
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancerAlexander T Wenzel, Devora Champa, Hrishi Venkatesh, et al.
Biopolymers|June 22, 2010
Characterization of a clinical polymer-drug conjugate using multiscale modelingLili X Peng, Anthony Ivetac, Akshay S Chaudhari, et al.
Bioconjugate Chemistry|January 25, 2021
Therapeutic Targeting of Tumor Cells Rich in LGR Stem Cell ReceptorsSongman Yu, Maria Carmen Mulero, Wannan Chen, et al.
International Journal of Nanomedicine|November 3, 2010
Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugateSang Van, Sanjib K Das, Xinghe Wang, et al.
ACS Central Science|December 18, 2018
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence MicroscopyMaria T Proetto, Cassandra E Callmann, John Cliff, et al.
Gynecologic Oncology|March 27, 2012
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group studyMichael A Gold, William E Brady, Heather A Lankes, et al.
Pageof 11